Series A launching Q4 2022

We have ambitious plans for ScubaTx™. The existing IP will act as platform from which we will build an innovation engine, fuelled by our multiple competitive advantages:

1. A unique technical solution to a large, growing global problem. Clear market pull for solutions that can offer reduced financial cost and burden on precious but overworked clinical staff.

2. Low clinical risk. Persufflation has been demonstrated to be effective in pancreas, kidney, liver, heart and composite tissue.

3. Low technical risk. A working prototype of the ScubaTx system has already been demonstrated to be effective in use with human organs. Our CTO has direct experience leading the development of a more complex organ preservation system (now successfully commercialised). Our CIO has the expertise to ensure we have class-leading technology underpinning the safety, security and performance of our products.

4. Strong barriers to entry via a brand new family of patent filings. Leading IP lawyers (Mathys & Squire).

5. Our CSO is a world-class clinical expert in organ preservation. He is supported by a strong and growing clinical advisory group, Newcastle University, and the NUTH NHS Trust. This network facilitates access to grant funding, human organs and future talent.

For more information, please contact us.